AGP Executive Report
Last update: 7 hours agoHospital safety under fire: Gaza’s Al-Ahli Arab Hospital was hit again by an IDF strike, with windows and doors blown out and responders delayed by fears of a second strike—raising fresh alarms about care access amid shortages. Biosimilars push in the Gulf: Mabwell signed a GCC licensing deal with Saudi SVAX for its aflibercept biosimilar 9MW0813, aiming to register, manufacture and commercialize across Saudi and other GCC markets. IBD treatment pipeline advances: Polpharma Biologics and Fresenius Kabi secured FDA and EMA acceptance for review of PB016, an IV vedolizumab biosimilar candidate for ulcerative colitis and Crohn’s disease. Biotech as a regional growth bet: A new wave of biotech investment and partnerships is emerging across the Middle East as governments diversify and build life-sciences capacity. Environmental health pressure in Iraq: Salinity and drought are worsening land degradation across Iraq, threatening food security and rural livelihoods. Gulf security drills: Bahrain hosted the “Bahrain Shield” exercise as Crown Prince Sheikh Hamdan attended, underscoring GCC coordination that can indirectly shape public health emergency readiness.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
